Search

Your search keyword '"HØIEGGEN, AUD"' showing total 281 results
Start Over Author "HØIEGGEN, AUD"
281 results on '"HØIEGGEN, AUD"'

1. Effect of Drug Monitoring on Adherence and Blood Pressure: A Multicenter Randomized Clinical Trial

Author

Halvorsen, Lene V, primary, Søraas, Camilla L, additional, Larstorp, Anne Cecilie K, additional, Hjørnholm, Ulla, additional, Kjær, Vibeke N, additional, Liestøl, Knut, additional, Aune, Arleen, additional, Olsen, Eirik, additional, Brobak, Karl Marius, additional, Bergland, Ola U, additional, Rognstad, Stine, additional, Aarskog, Nikolai R, additional, Heimark, Sondre, additional, Fadl Elmula, Fadl Elmula M, additional, Gerdts, Eva, additional, Mo, Rune, additional, Solbu, Marit D, additional, Opdal, Mimi S, additional, Kjeldsen, Sverre E, additional, Rostrup, Morten, additional, and Høieggen, Aud, additional

Published
2024
Full Text
View/download PDF

2. TEN YEAR FOLLOW-UP OF PATIENTS WITH RESISTANT HYPERTENSION RANDOMIZED TO RENAL DENERVATION OR ANTIHYPERTENSIVE DRUG TREATMENT

Author

Halvorsen, Lene, primary, Larstorp, Anne Cecilie K., additional, Søraas, Camilla L., additional, Hoffmann, Pavel, additional, Fossum, Eigil, additional, Haig, Ylva, additional, Stenehjem, Aud E., additional, Rostrup, Morten, additional, Fadl Elmula, Fadl Elmula M., additional, Kjeldsen, Sverre E., additional, and Høieggen, Aud, additional

Published
2024
Full Text
View/download PDF

3. Development of UHPLC-MS/MS methods to quantify 25 antihypertensive drugs in serum in a cohort of patients treated for hypertension

Author

Thorstensen, Christian W., Clasen, Per-Erik, Rognstad, Stine, Haldsrud, Renate, Føreid, Siri, Helstrøm, Trine, Bergland, Ola Undrum, Halvorsen, Lene Vernås, Aune, Arleen, Olsen, Eirik, Brobak, Karl Marius, Høieggen, Aud, Gustavsen, Ingebjørg, Larstorp, Anne Cecilie K., Søraas, Camilla Lund, and Opdal, Mimi Stokke

Published
2022
Full Text
View/download PDF

4. Novel biomarkers in patients with uncontrolled hypertension with and without kidney damage

Author

Brobak, Karl Marius, primary, Halvorsen, Lene V., additional, Aass, Hans Christian D., additional, Søraas, Camilla L., additional, Aune, Arleen, additional, Olsen, Eirik, additional, Bergland, Ola Undrum, additional, Rognstad, Stine, additional, Blom, Kjersti B., additional, Birkeland, Jon Arne K., additional, Høieggen, Aud, additional, Larstorp, Anne Cecilie K., additional, and Solbu, Marit D., additional

Published
2024
Full Text
View/download PDF

5. Directly Observed Therapy in Hypertension (DOT-HTN)

Author

Hjørnholm, Ulla, Aamodt, Mikaela, Larstorp, Anne Cecilie, Fadl Elmula, Fadl Elmula M., Høieggen, Aud, Andersen, Marit Helen, Kjeldsen, Sverre E., Mancia, Giuseppe, Series Editor, Agabiti Rosei, Enrico, Series Editor, and Burnier, Michel, editor

Published
2018
Full Text
View/download PDF

6. Diabetes og kronisk nyresykdom

Author

Mariampillai, Julian Eek, primary, Halvorsen, Lene Vernås, primary, Larstorp, Anne Cecilie, primary, Heimark, Sondre, primary, Waldum-Grevbo, Bård, primary, Kjeldsen, Sverre Erik, primary, Nordby, Gudmund, primary, Stenehjem, Aud-Eldrid, primary, Berg, Jens Petter, primary, and Høieggen, Aud, primary

Published
2023
Full Text
View/download PDF

8. SHOULD MIDDLE-AGED AND OLDER HIGH-RISK HYPERTENSIVE PATIENTS WITH DIABETES BE TREATED TO TARGET BT <130/80 MMHG?

Author

Olsen, Eirik, primary, Søraas, Camilla Lund, additional, Mancia, Giuseppe, additional, Heimark, Sondre, additional, Mehlum, Maria H., additional, Liestöl, Knut, additional, Kjeldsen, Sverre E., additional, Høieggen, Aud, additional, Rostrup, Morten, additional, Mo, Rune, additional, Julius, Stevo, additional, and Weber, Michael, additional

Published
2023
Full Text
View/download PDF

11. The Association between Urinary Sodium-Potassium Ratio, Kidney Function, and Blood Pressure in a Cohort from the General Population.

Author

Brobak, Karl Marius, Melsom, Toralf, Eriksen, Bjørn Odvar, Høieggen, Aud, Norvik, Jon Viljar, and Solbu, Marit Dahl

Subjects
KIDNEY physiology, BLOOD pressure, HIGH-salt diet, SALT-free diet, CHRONIC kidney failure
Abstract

Introduction: Subclinical kidney dysfunction may contribute to salt-sensitive hypertension. We assessed the association between the urinary sodium-potassium ratio (Na/K ratio) and blood pressure (BP) in a general population cohort without diabetes, chronic kidney disease, cardiovascular disease, or treated hypertension. We investigated whether any such association was mediated by the kidney function markers measured glomerular filtration rate (mGFR), urinary albumin-creatinine ratio (ACR), and urinary epidermal growth factor-creatinine ratio (EGF-Cr). Methods: The Tromsø Study is a population-based study of inhabitants of the municipality of Tromsø, Northern Norway. Participants aged 50–62 years, without diabetes, chronic kidney disease, or cardiovascular disease, were invited to the substudy Renal Iohexol Clearance Survey in Tromsø 6 (RENIS-T6; 2007–09). For the present study, we excluded participants reporting the use of 1 or more antihypertensive agents, leaving 1,311 RENIS-T6 participants for a cross-sectional analysis. We measured office BP, 24-h ambulatory blood pressure (ABP), and mGFR using iohexol clearance. Na/K ratio, ACR, and EGF-Cr were measured in morning urine samples. Results: Urinary Na/K ratio was significantly associated with systolic office BP and ABP independently of cardiovascular risk factors and kidney function markers. A one-standard deviation unit increase in the Na/K ratio was associated with increased systolic ABP by 1.0 (0.3–1.6) mm Hg. Urinary Na/K ratio showed a stronger association with office BP than ABP. EGF-Cr, ACR, and mGFR did not mediate the relationship between urinary Na/K ratio and systolic BP. Conclusions: In a representative sample of the middle-aged North-European population without diabetes, chronic kidney disease, cardiovascular disease, or treated hypertension, there was a consistent association between urinary Na/K ratio and BP. The association with BP was not mediated through kidney function measures, suggesting a relationship between a diet with high sodium and low potassium and higher BP regardless of kidney function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy

Author

Halvorsen, Lene V., primary, Bergland, Ola U., additional, Søraas, Camilla L., additional, Larstorp, Anne Cecilie K., additional, Hjørnholm, Ulla, additional, Kjær, Vibeke N., additional, Kringen, Marianne K., additional, Clasen, Per‐Erik, additional, Haldsrud, Renate, additional, Kjeldsen, Sverre E., additional, Rostrup, Morten, additional, Fadl Elmula, Fadl Elmula M., additional, Opdal, Mimi S., additional, and Høieggen, Aud, additional

Published
2022
Full Text
View/download PDF

16. IMPLICATIONS OF CYP2D6 POLYMORPHISMS FOR THERAPEUTIC DRUG MONITORING IN PATIENTS WITH HYPERTENSION

Author

Halvorsen, Lene Vernås, primary, Gognstad, Stine, additional, Søraas, Camilla Lund, additional, Ågnes, Camilla, additional, Hjørnholm, Ulla, additional, Kjær, Vibeke Norheim, additional, Svarstad, Anja Camilla, additional, Bergland, Ola Undrum, additional, Brobak, Karl Marius, additional, Aune, Arleen, additional, Olsen, Eirik, additional, Solbu, Marit D., additional, Gerdts, Eva, additional, Mo, Rune, additional, Fadl Elmula, Fadl Elmula M., additional, Rostrup, Morten, additional, Kjeldsen, Sverre E., additional, Tuv, Silja Skogstad, additional, Høieggen, Aud, additional, Larstorp, Anne Cecilie K., additional, and Opdal, Mimi Stokke, additional

Published
2022
Full Text
View/download PDF

18. Associations of urinary orosomucoid, N-acetyl-β-D-glucosaminidase, and albumin with blood pressure and hypertension during 7 years of follow-up. The Tromsø Stud

Author

Brobak, Karl Marius, Andreassen, Runa Marie, Melsom, Toralf, Høieggen, Aud, Norvik, Jon Viljar, and Solbu, Marit Dahl

Abstract

Purpose: Subclinical chronic kidney disease is known to exacerbate hypertension and progression of kidney damage. In order to initiate timely interventions, early biomarkers for this vicious circle are needed. Our aim was to describe the cross-sectional associations of urinary orosomucoid and urinary N-acetyl-b-D-glucosaminidase (NAG) with blood pressure and the longitudinal associations of urinary orosomucoid and NAG to hypertension after 7 years, and to compare the strength of these associations to the urinary albumin excretion (UAE). Material and methods: The Tromsø Study is a population-based, prospective study of inhabitants of the municipality of Tromsø, Northern Norway. Morning spot urine samples were collected on three consecutive days in the Tromsø 6 survey (2007–2008). We assessed the crosssectional associations of urinary orosomucoid, NAG and UAE with blood pressure in Tromsø 6. In a cohort of participants attending Tromsø 6 and Tromsø 7 (2015–2016), we studied whether urinary biomarkers were longitudinally associated with hypertension. Results: A total of 7197 participants with a mean age of 63.5 years (SD 9.2), and a mean blood pressure of 141/78 mmHg (SD 23.0/10.6), were included in the study. Orosomucoid and UAE, but not NAG, was significantly associated with systolic and diastolic blood pressure in all the crude and multivariable cross-sectional analyses. Orosomucoid had consistently, although marginally, stronger associations with blood pressure. Incident hypertension at follow-up (Tromsø 7) was consistently significantly associated with urinary orosomucoid, but not urinary NAG or UAE. However, the standardized regression coefficients for orosomucoid were only marginally stronger than the standardized regression coefficients for ACR. Conclusion: In a cohort from the general population urine orosomucoid had a stronger crosssectional association with blood pressure than UAE. After 7 years, urine orosomucoid showed the strongest association with incident hypertension. There were varying and weak associations between U-NAG, blood pressure and hypertension.

Published
2022

19. Berit Holten

Author

Høieggen, Aud, primary, Sverre, Jan Marcus, primary, Kittelsen, Peter, primary, Sørensen, Trine, primary, and Svendsen, Thomas, primary

Published
2022
Full Text
View/download PDF

20. Detection of Nonadherence to Antihypertensive Treatment by Measurements of Serum Drug Concentrations

Author

Bergland, Ola Undrum, primary, Halvorsen, Lene V., additional, Søraas, Camilla L., additional, Hjørnholm, Ulla, additional, Kjær, Vibeke N., additional, Rognstad, Stine, additional, Brobak, Karl Marius, additional, Aune, Arleen, additional, Olsen, Eirik, additional, Fauchald, Ylva M., additional, Heimark, Sondre, additional, Thorstensen, Christian W., additional, Liestøl, Knut, additional, Solbu, Marit D., additional, Gerdts, Eva, additional, Mo, Rune, additional, Rostrup, Morten, additional, Kjeldsen, Sverre E., additional, Høieggen, Aud, additional, Opdal, Mimi S., additional, Larstorp, Anne Cecilie K., additional, and Fadl Elmula, Fadl Elmula M., additional

Published
2021
Full Text
View/download PDF

21. PHYSICIAN- AND PATIENT REPORTED ADHERENCE TO ANTIHYPERTENSIVE DRUGS VERIFIED BY SERUM DRUG CONCENTRATION

Author

Bergland, Ola Undrum, primary, Søraas, Camilla Lund, additional, Halvorsen, Lene Vernås, additional, Rognstad, Stine, additional, Hjørnholm, Ulla, additional, Kjær, Vibeke, additional, Opdal, Mimi Stokke, additional, Rostrup, Morten, additional, Larstorp, Anne Cecilie, additional, Høieggen, Aud, additional, and Fadl Elmula, Fadl Elmula M., additional

Published
2021
Full Text
View/download PDF

22. SERUM CONC. OF ANTIHYPERTENSIVE DRUGS MAY REVEAL NON-ADHERENCE IN PATIENTS CONSIDERED TO HAVE TRUE TREATMENT RESISTANT HYPERTENSION ASSESSED BY DIRECTLY OBSERVED THERAPY

Author

Halvorsen, Lene Vernås, primary, Bergland, Ola Undrum, additional, Søraas, Camilla Lund, additional, Larstorp, Anne Cecilie Kje, additional, Hjørnholm, Ulla, additional, Kjær, Vibeke Norheim, additional, Mula, Fadl El Mula Fadl El, additional, Opdal, Mimmi Stokke, additional, and Høieggen, Aud, additional

Published
2021
Full Text
View/download PDF

29. Beliefs about medicines in dialysis patients and after renal transplantation

Author

Drangsholt, Sarah H, Cappelen, Ulrik W, Lippe, Nanna von der, Høieggen, Aud, Os, Ingrid, and Brekke, Fredrik B.

Abstract

Introduction: Patients with end‐stage renal disease are burdened by a complex medication regimen, but little is known about the belief about medicine among dialysis‐ and renal transplant (RTX) patients. Patients’ beliefs about medicines may influence drug adherence and thereby affect morbidity and mortality. The aim of the present study was to assess the beliefs about medicine in dialysis as well as after RTX. Methods: In a prospective study, 301 dialysis patients were followed for up to 5.5 years during which time 142 had been transplanted. Out of the transplanted patients, 110 were eligible for inclusion. The Beliefs about Medicine Questionnaire (BMQ) was used to assess the beliefs in dialysis and after transplantation. BMQ in dialysis was also compared to that of the general Norwegian population (n = 426). Multiple linear regression analyses were performed with BMQ subscales as dependent variables and sociodemographic and clinical data as independent variables. Findings: Median age in dialysis was 62 (IQR 50‐73) years, 66.1% were male and 80.7% were treated with hemodialysis. When in dialysis, 98.2% strongly believed their medications were necessary, while 34.4% reported strong concerns. Furthermore, 17.3% believed their medications to be harmful and 38.6% believed that doctors overprescribed medicines. The Necessity‐concern differential had a positive score in 92.6% of the patients. Follow‐up time was 55 (IQR 50‐59) months. After transplantation, there was an increase in the patient‐reported necessity of medication (21.9 ± 2.7 vs. 23.8 ± 1.9, P < 0.001) compared to while in dialysis. Correlations were found between patient beliefs and education, age, and depression. Discussion: Although positive beliefs about medicines increase after transplantation, concerns are high in both dialysis and after RTX. Implementing the BMQ routinely in the clinical evaluation of dialysis‐ and RTX patients may help to identify patients with increased risk for medical nonadherence.

Published
2019

33. The impact of serum uric acid on cardiovascular outcomes in the LIFE study

Author

Høieggen, Aud, Alderman, Michael H., Kjeldsen, Sverre E., Julius, Stevo, Devereux, Richard B., de Faire, Ulf, Fyhrquist, Frej, Ibsen, Hans, Kristianson, Krister, Lederballe-Pedersen, Ole, Lindholm, Lars H., Nieminen, Markku S., Omvik, Per, Oparil, Suzanne, Wedel, Hans, Chen, Cong, Dahlöf, Björn, and for the LIFE Study Group

Published
2004
Full Text
View/download PDF

42. Renal sympathetic denervation lowers systemic vascular resistance in true treatment-resistant hypertension.

Author

Bergo, Kaja K., Larstorp, Anne C., Hoffmann, Pavel, Hjørnholm, Ulla, Cataliotti, Alessandro, Høieggen, Aud, Rostrup, Morten, and Fadl Elmula, Fadl Elmula M.

Subjects
VASCULAR resistance, HYPERTENSION, DENERVATION, BLOOD pressure, DRUG control
Abstract

Renal sympathetic denervation (RDN) is again gaining interest as recent well-designed trials have demonstrated reduced ambulatory blood pressure (BP) after RDN. However, the hemodynamic mechanisms have not been elucidated. We aimed for the first time to investigate the effect of RDN on the "Hallmark of Hypertension" namely increased systemic vascular resistance index (SVRI). We investigated SVRI change in patients with true treatment-resistant hypertension randomised to RDN (n = 9) or drug adjusted control (n = 9). Treatment-resistant hypertension was defined as office systolic BP ≥ 140 mmHg despite ≥ 3 antihypertensive drugs including a diuretic. True treatment-resistant hypertension was confirmed prior to inclusion with ambulatory daytime systolic BP ≥ 135 mmHg immediately after witnessed intake of antihypertensive drugs. Hemodynamic variables were recorded with thoracic impedance cardiography at baseline and at three and six months follow-up after RDN. This non-invasive method also guided further tailoring of drug treatment in the control group aiming to normalise hemodynamic variables and BP. From three to six months follow-up after RDN, SVRI decreased with a median of −611 dyn*s*m2/cm5 [IQR −949 to −267] (p < 0.01), while supine mean BP decreased with a median of −11 mmHg [IQR −21 to −3] (p = 0.02). In the same period, SVRI in the control group was reduced with −674 dyn*s*m2/cm5 [IQR −1,309 to −340] (p < 0.01), while supine mean BP decreased with −15 mmHg [IQR −29 to −6] (p = 0.01). Thus, hemodynamic variables and BP in the two groups normalised in parallel. Our data suggest that in patients with true treatment-resistant hypertension, renal sympathetic denervation lowers BP by reducing systemic vascular resistance of similar size as in the control group with careful individual selection of antihypertensive drugs and dose titration. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. The randomised Oslo study of renal denervation vs. Antihypertensive drug adjustments: efficacy and safety through 7 years of follow-up.

Author

Bergland, Ola Undrum, Søraas, Camilla Lund, Larstorp, Anne Cecilie K., Halvorsen, Lene V., Hjørnholm, Ulla, Hoffman, Pavel, Høieggen, Aud, and Fadl Elmula, Fadl Elmula M.

Subjects
DRUG efficacy, DENERVATION, BLOOD pressure, HYPERTENSION, DIURETICS
Abstract

The blood pressure (BP) lowering effect of renal sympathetic denervation (RDN) in treatment-resistant hypertension shows variation amongst the existing randomised studies. The long-term efficacy and safety of RDN require further investigation. For the first time, we report BP changes and safety up to 7 years after RDN, compared to drug adjustment in the randomised Oslo RDN study. Patients with treatment-resistant hypertension, defined as daytime systolic ambulatory BP ≥135 mmHg after witnessed intake of ≥3 antihypertensive drugs including a diuretic, were randomised to either RDN (n = 9) or drug adjustment (n = 10). The initial primary endpoint was the change in office BP after 6 months. The RDN group had their drugs adjusted after 1 year using the same principles as the Drug Adjustment group. Both groups returned for long-term follow-up after 3 and 7 years. The decrease in office BP and ambulatory BP (ABPM) after 6 months did not persist, but gradually increased in both groups. From 6 months to 7 years follow-up, mean daytime systolic ABPM increased from 142 ± 10 to 145 ± 15 mmHg in the RDN group, and from 133 ± 11 to 137 ± 13 mmHg in the Drug Adjustment group, with the difference between them decreasing. In a mixed factor model, a significantly different variance was found between the groups in daytime systolic ABPM (p =.04) and diastolic ABPM (p =.01) as well as office diastolic BP (p<.01), but not in office systolic BP (p =.18). At long-term follow-up we unveiled no anatomical- or functional renal impairment in either group. BP changes up to 7 years show a tendency towards a smaller difference in BPs between the RDN and drug adjustment patients. Our data support RDN as a safe procedure, but it remains non-superior to intensive drug adjustment 7 years after the intervention. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

44. Apparent treatment resistant hypertension- patient-physician relationship and ethical issues

Author

Høieggen, Aud

Abstract

BACKGROUND: Poor drug adherence is a major cause of apparent treatment-resistant hypertension. As a consequence, several methods have been developed and attempted implemented in clinical practice to reveal non-adherence and to monitor drug adherence. There are, however, several hitherto unresolved ethical aspects regarding potential methods for drug monitoring in these patients. RESULTS: The most striking challenge is the balance between patient autonomy and the physician's desire for the patient to adhere to the prescribed therapy. Also, methods for monitoring must only be implemented in the treatment of well-informed and consenting patients. Major resources are used on non-adherent patients; how long the physician should encourage continuation of treatment is an important question. CONCLUSIONS: We believe that physicians should reflect and discuss these potential challenges, and that patient education, information and a solid patient-physician relationship are essential for achieving drug adherence. Methods for monitoring adherence represent, however, a useful and often necessary supplement. This research has been accepted and published in Blood Pressure. © 2017 Taylor & Francis

Published
2017

45. CAN SERUM CONSENTRATION MEASUREMENTS OF ANTIHYPERTENSIVE DRUGS IMPROVE BLOOD PRESSURE CONTROL? A MULTICENTER DOUBLE BLINDED RANDOMIZED CONTROLLED TRIAL.

Author

Halvorsen, Lene Vernås, Søraas, Camilla Lund, Larstorp, Anne Cecilie K., Bergland, Ola Undrum, Brobak, Karl Marius, Aune, Arleen, Olsen, Eirik, Rognstad, Stine, Heimark, Sondre, Aarskog, Nikolai Ravn, Hjørnholm, Ulla, Kjær, Vibeke Nordheim, Elmula, Fadl Elmula M. Fadl, Solbu, Marit Dahl, Gerdts, Eva, Mo, Rune, Opdal, Mimi Stokke, Rostrup, Morten, Kjeldsen, Sverre Erik, and Høieggen, Aud

Published
2023
Full Text
View/download PDF

47. Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

Author

Kjeldsen, Sverre E, Lyle, Paulette A, Kizer, Jorge R, Oparil, Suzanne, Høieggen, Aud, and Os, Ingrid

Subjects
hypertension, Review, stroke, hydrochlorothiazide, Losartan, combination therapy, Risk Factors, cardiovascular system, Humans, Drug Therapy, Combination, angiotensin receptor blocker, Angiotensin II Type 1 Receptor Blockers, hormones, hormone substitutes, and hormone antagonists, Antihypertensive Agents, circulatory and respiratory physiology
Abstract

A fixed-dose combination of losartan/hydrochlorothiazide (HCTZ) therapy may be a logical choice for antihypertensive treatment, including for initial therapy in patients with blood pressure elevation >20/10 mmHg above treatment target. The renin–angiotensin– aldosterone–system-activating effect of hydrochlorothiazide augments the efficacy of blocking the angiotensin II type 1 (AT1) receptor with losartan. Some adverse effects associated with hydrochlorothiazide, including increased risk for new-onset diabetes mellitus, may be offset by losartan. Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group. The efficacy, tolerability, and convenience of losartan/HCTZ combination therapy may increase patient compliance and lower risk for stroke, a devastating outcome in patients with hypertension.

Published
2007

49. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension.

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Berra , Elena, Azizi, Michel, Capron, Arnaud, Høieggen, Aud, Rabbia, Franco, Kjeldsen, Sverre E, Staessen, Jan A, Wallemacq, Pierre, Persu, Alexandre, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, UCL - (SLuc) Service de pathologie cardiovasculaire, UCL - (SLuc) Service de biochimie médicale, Berra , Elena, Azizi, Michel, Capron, Arnaud, Høieggen, Aud, Rabbia, Franco, Kjeldsen, Sverre E, Staessen, Jan A, Wallemacq, Pierre, and Persu, Alexandre

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results